Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Gothenburg, November 13, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company's commercially available iTANK platform, announces today that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research.
The grant is awarded to Professor Magnus Essand in his role as an employed academic researcher at Uppsala University and forms a natural part of the academic research activities. The funding, which spans three years, enables continued work for Essand's research group in the CAR T-cell field. With annual funding of 2.5 MSEK - an increase from the previous 1.75 MSEK - the group can now allocate greater resources to the research than before.